CA125单项与多项肿瘤指标联合检测在卵巢癌诊断中的价值分析
|
摘要
目的分析CA125单项与多项肿瘤指标联合检测在卵巢癌诊断中的价值。方法方便选取该院2017年1—12月收治的A、B、C 3组不同的患者,各45例作为该次实验的研究对象,采用化学发光免疫检测法对3组女性血清中的相关含量进行测定,比较不同检测对卵巢癌的诊断效率。结果 A组患者血清中CA125含量达到(232.1±64.2)U/mL,显著高于B组的(18.2±5.8)U/mL、C组的(16.1±6.5)U/mL。A组患者血清中CA199、CA153、CEA的含量也显著高于B组和C组,差异有统计学意义(P<0.05);但B组患者和C组血清中CA125、CA199、CA153、CEA的含量比较,差异无统计学意义(P>0.05);A组CA125、CA199、CA153、CEA的阳性检出率分别为95.6%、40.0%、60.0%、22.2%,显著高于B组(35.5%、37.8%、2.2%、6.7%)和C组(0.0%、2.2%、0.0%、0.0%),而各单项肿瘤指标阳性检出率显著低于多项联合检测的阳性率,差异有统计学意义(P<0.05)。结论采用多项肿瘤指标联合检测不仅提高了卵巢癌的阳性率、诊断准确率,而且有利于早日发现卵巢癌,在卵巢癌的诊断中具有重要的意义和价值。
Objective To analyze the value of combined detection of CA125 single and multiple tumor markers in the diagnosis of ovarian cancer. Methods 45 patients in each group A, B, and C in the hospital from January to December 2017 were convenient selected as the subjects of this experiment. The chemiluminescence immunoassay was used to detect the correlation among the three groups of female sera. The content was measured to compare the diagnostic efficiency of different tests for ovarian cancer. Results The serum CA125 level in group A was(232.1 ±64.2) U/mL, which was significantly higher than that in group B(18.2±5.8) U/mL and group C(16.1±6.5) U/mL. The serum levels of CA199, CA153 and CEA in group A were also significantly higher than those in group B and C(P <0.05). The difference was statistically significant;however, the serum levels of CA125, CA199, CA153 and CEA in group B and group C were significantly higher. There was no significant difference between the two groups(P>0.05). The positive rates of CA125, CA199, CA153 and CEA in group A were 95.6%, 40.0%, 60.0%, and 22.2%, respectively, which were significantly higher than those in group B(35.5%, 37.8%,2.2%, 6.7%) and group C(0.0%, 2.2%, 0.0%, 0.0%), and the positive detection rate of each single tumor index was significantly lower than that of multiple combined tests, the difference was statistically significant(P<0.05). Conclusion The combined detection of multiple tumor markers not only improves the positive rate and diagnostic accuracy of ovarian cancer, but also helps early detection of ovarian cancer. It has important significance and value in the diagnosis of ovarian cancer.
Objective To analyze the value of combined detection of CA125 single and multiple tumor markers in the diagnosis of ovarian cancer. Methods 45 patients in each group A, B, and C in the hospital from January to December 2017 were convenient selected as the subjects of this experiment. The chemiluminescence immunoassay was used to detect the correlation among the three groups of female sera. The content was measured to compare the diagnostic efficiency of different tests for ovarian cancer. Results The serum CA125 level in group A was(232.1 ±64.2) U/mL, which was significantly higher than that in group B(18.2±5.8) U/mL and group C(16.1±6.5) U/mL. The serum levels of CA199, CA153 and CEA in group A were also significantly higher than those in group B and C(P <0.05). The difference was statistically significant;however, the serum levels of CA125, CA199, CA153 and CEA in group B and group C were significantly higher. There was no significant difference between the two groups(P>0.05). The positive rates of CA125, CA199, CA153 and CEA in group A were 95.6%, 40.0%, 60.0%, and 22.2%, respectively, which were significantly higher than those in group B(35.5%, 37.8%,2.2%, 6.7%) and group C(0.0%, 2.2%, 0.0%, 0.0%), and the positive detection rate of each single tumor index was significantly lower than that of multiple combined tests, the difference was statistically significant(P<0.05). Conclusion The combined detection of multiple tumor markers not only improves the positive rate and diagnostic accuracy of ovarian cancer, but also helps early detection of ovarian cancer. It has important significance and value in the diagnosis of ovarian cancer.
引文
[1]向田,刘杲.CA125单项与多项肿瘤指标联合检测在卵巢癌诊断中的价值分析[J].河北医药,2017(4):520-523.
[2]屈明利,邓晓红,赵侃侃,等.血清CA125、CEA、AFP联合检测在卵巢恶性肿瘤诊断中的临床价值[J].实用癌症杂志,2017,32(7):1065-1068.
[3]郑红云,于奇,申复进,等.血清HE4、CA125和CA199联合检测对卵巢癌早期诊断的临床研究[J].国际检验医学杂志,2017(19):2680-2682.
[4]冯先华,郗娟.CA125、CA153、CA199和CEA联合检测在上皮性卵巢癌中的诊断价值[J].国际检验医学杂志,2014(14):1846-1847,1850.
[5]周德众.血清HE4、CA125和TSGF联合检测在卵巢肿瘤中的诊断价值[J].航空航天医学杂志,2015(7):798-799.
[6]李秀华,冯梅,钟沛霖,等.血清HE4联合CA125、CA199检测对上皮性卵巢癌的诊断价值[J].宁夏医科大学学报,2015(8):959-962.
[7]朱珏,张珂,马胜林.CA125单项与多项肿瘤指标联合检测在卵巢癌诊断中的比较[J].国际妇产科学杂志,2015(5):591-593.
[8]颜宇博,李丹.CA125单项与多项肿瘤指标联合检测在卵巢癌诊断中的比较[J].中国实用医药,2016(11):35-36.
[2]屈明利,邓晓红,赵侃侃,等.血清CA125、CEA、AFP联合检测在卵巢恶性肿瘤诊断中的临床价值[J].实用癌症杂志,2017,32(7):1065-1068.
[3]郑红云,于奇,申复进,等.血清HE4、CA125和CA199联合检测对卵巢癌早期诊断的临床研究[J].国际检验医学杂志,2017(19):2680-2682.
[4]冯先华,郗娟.CA125、CA153、CA199和CEA联合检测在上皮性卵巢癌中的诊断价值[J].国际检验医学杂志,2014(14):1846-1847,1850.
[5]周德众.血清HE4、CA125和TSGF联合检测在卵巢肿瘤中的诊断价值[J].航空航天医学杂志,2015(7):798-799.
[6]李秀华,冯梅,钟沛霖,等.血清HE4联合CA125、CA199检测对上皮性卵巢癌的诊断价值[J].宁夏医科大学学报,2015(8):959-962.
[7]朱珏,张珂,马胜林.CA125单项与多项肿瘤指标联合检测在卵巢癌诊断中的比较[J].国际妇产科学杂志,2015(5):591-593.
[8]颜宇博,李丹.CA125单项与多项肿瘤指标联合检测在卵巢癌诊断中的比较[J].中国实用医药,2016(11):35-36.